



RECEIVED

MAR 05 2002

3-7-02

TECH CENTER 1600/2900

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
ROLF BJERKVIG) : Examiner: J. Angell
Appln. No.: 09/763,682) : Group Art Unit: 1633
Filed: February 26, 2001) :
For: ALGINATE CAPSULES FOR USE) March 4, 2002
IN THE TREATMENT OF) :
BRAIN TUMOR (As Amended))

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO ELECTION/RESTRICTION REQUIREMENT

Sir:

In the Office Action mailed December 4, 2001, the Examiner restricted the claimed invention into two groups: Group I, Claims 12, 13, 17 and 22; and Group II, Claims 12 and 23. The Examiner considered Claims 14-16, 18-21 and 24-28 to be generic to Groups I and II. In addition, the Examiner restricted the claims in each group into a set of species.

Applicant elects to proceed with the examination of the claims of Group I. Within Group I, Applicant elects claims specific for the species of "a molecule that is capable of affecting tumor neovascularization" if no generic claim is finally held to be allowable. The claims readable on the elected species are Claims 12, 13, 17, and 22.

Applicant's undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should continue to be directed to our address given below.

Respectfully submitted,


John W. Behringer
Attorney for Applicant
John W. Behringer
Registration No. 23,086

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200